Oncotarget

Research Papers:

Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer

Po-Han Lin, Wen-Hung Kuo, Ai-Chu Huang, Yen-Shen Lu, Ching-Hung Lin, Sung-Hsin Kuo, Ming-Yang Wang, Chun-Yu Liu, Fiona Tsui-Fen Cheng, Ming-Hsin Yeh, Huei-Ying Li, Yu-Hsuan Yang, Yu-Hua Hsu, Sheng-Chih Fan, Long-Yuan Li, Sung-Liang Yu, King-Jen Chang, Pei-Lung Chen, Yen-Hsuan Ni and Chiun-Sheng Huang _

PDF  |  HTML  |  Supplementary Files  |  Order a Reprint

Oncotarget. 2016; 7:8310-8320. https://doi.org/10.18632/oncotarget.7027

Metrics: PDF 2016 views  |   HTML 1993 views  |   ?  


Abstract

Po-Han Lin1,2, Wen-Hung Kuo3, Ai-Chu Huang2, Yen-Shen Lu4, Ching-Hung Lin4, Sung-Hsin Kuo4, Ming-Yang Wang3, Chun-Yu Liu6, Fiona Tsui-Fen Cheng7, Ming-Hsin Yeh8, Huei-Ying Li2, Yu-Hsuan Yang2, Yu-Hua Hsu2, Sheng-Chih Fan2, Long-Yuan Li9, Sung-Liang Yu10, King-Jen Chang11, Pei-Lung Chen2, Yen-Hsuan Ni2,5, Chiun-Sheng Huang3

1Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan

2Department of Medical Genetics, National Taiwan University Hospital, Taipei, Taiwan

3Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan

4Department of Medical Oncology, National Taiwan University Hospital, Taipei, Taiwan

5Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan

6Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan

7Department of Surgery, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan

8Department of Surgery, Chung Shan Medical University Hospital, Taichung, Taiwan

9Graduate Institute of Cancer Biology, China Medical University, Taichung, Taiwan

10Center of Genomic Medicine, National Taiwan University, Taipei, Taiwan

11Department of Surgery, Cheng Ching Hospital, Taichung, Taiwan

Correspondence to:

Chiun-Sheng Huang, e-mail: huangcs@ntu.edu.tw

Yen-Hsuan Ni, e-mail: yhni@ntu.edu.tw

Keywords: multiple gene sequencing, hereditary breast cancer, BRCA, variant of uncertain significance, genetic counseling

Received: July 02, 2015     Accepted: January 01, 2016     Published: January 27, 2016

ABSTRACT

Since BRCA mutations are only responsible for 10–20% of cases of breast cancer in patients with early-onset or a family history and since next-generation sequencing technology allows the simultaneous sequencing of a large number of target genes, testing for multiple cancer-predisposing genes is now being considered, but its significance in clinical practice remains unclear. We then developed a sequencing panel containing 68 genes that had cancer risk association for patients with early-onset or familial breast cancer. A total of 133 patients were enrolled and 30 (22.6%) were found to carry germline deleterious mutations, 9 in BRCA1, 11 in BRCA2, 2 in RAD50, 2 in TP53 and one each in ATM, BRIP1, FANCI, MSH2, MUTYH, and RAD51C. Triple-negative breast cancer (TNBC) was associated with the highest mutation rate (45.5%, p = 0.025). Seven of the 9 BRCA1 mutations and the single FANCI mutation were in the TNBC group; 9 of the 11 BRCA2, 1 of the 2 RAD50 as well as BRIP1, MSH2, MUTYH, and RAD51C mutations were in the hormone receptor (HR)(+)Her2(−) group, and the other RAD50, ATM, and TP53 mutations were in the HR(+)Her2(+) group. Mutation carriers were considered as high-risk to develop malignancy and advised to receive cancer screening. Screening protocols of non-BRCA genes were based on their biologic functions; for example, patients carrying RAD51C mutation received a screening protocol similar to that for BRCA, since BRCA and RAD51C are both involved in homologous recombination. In conclusion, we consider that multiple gene sequencing in cancer risk assessment is clinically valuable.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 7027